Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to better tap into America's mass market for weight-loss drugs. https://www.japantimes.co.jp/business/2025/10/22/companies/novo-nordisk-board-us-consumers/?utm_medium=Social&utm_source=mastodon #business #companies #wegovy #pharmaceuticals #novonordisk
Obésité: ces médecins qui rusent pour soigner les moins aisés
Le médicament anti-obésité #Wegovy de #NovoNordisk, hors de prix, n’est pas remboursé en France alors que la maladie touche davantage les populations précaires. Des médecins prescrivent son traitement anti-diabétique, l’Ozempic, moins cher, pour venir en aide aux moins riches.
Par Rozenn Le Saint › https://www.mediapart.fr/journal/france/150925/obesite-ces-medecins-qui-rusent-pour-soigner-les-moins-aises?at_medium=rs-cm&at_campaign=mastodon&at_account=mediapart
Chinese companies are racing to make generic versions of popular branded weight-loss drugs after regulators restricted sale of cheap copies, slowing demand for raw ingredients the firms supplied over the past two years. https://www.japantimes.co.jp/business/2025/09/03/companies/chinese-companies-generics-us-weight/?utm_medium=Social&utm_source=mastodon #business #companies #china #pharmaceuticals #wegovy #elililly#novonordisk #fda